0QZU.LSE Vertex Pharmaceuticals Inc.

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
59.1x
P/B
-
ROE
21.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0QZU.LSE undervalued?

Graham number

The Graham number of Vertex Pharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vertex Pharmaceuticals Inc. fundamental analysis

No fundamental analysis for Vertex Pharmaceuticals Inc. yet.

Vertex Pharmaceuticals Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for …

Full company profile